Dydo Pharma
Japanese pharmaceutical company specializing in rare neurological disease treatments, with recent approval of Firdapse® for Lambert-Eaton myasthenic syndrome in Japan.
Private Company
Funding information not available
AI Company Overview
Japanese pharmaceutical company specializing in rare neurological disease treatments, with recent approval of Firdapse® for Lambert-Eaton myasthenic syndrome in Japan.
Technology Platform
Small molecule development focused on potassium channel blockers, particularly amifampridine phosphate (3,4-diaminopyridine) for neuromuscular junction disorders.
Opportunities
Risk Factors
Competitive Landscape
Competes with other amifampridine products globally (like Ruzurgi®) but holds first approved product advantage in Japan for LEMS treatment; differentiation through focused rare disease expertise and efficient Japanese regulatory execution.